International Journal of Hematology

, Volume 91, Issue 5, pp 844–849

Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports

  • Tatsuya Yoshida
  • Shigeru Kusumoto
  • Atsushi Inagaki
  • Fumiko Mori
  • Asahi Ito
  • Masaki Ri
  • Takashi Ishida
  • Hirokazu Komatsu
  • Shinsuke Iida
  • Fuminaka Sugauchi
  • Yasuhito Tanaka
  • Masashi Mizokami
  • Ryuzo Ueda
Original Article

Abstract

It was recently reported that hepatitis B virus (HBV) reactivation had occurred in HBsAg-negative lymphoma patients who received rituximab plus steroid combination chemotherapy. HBV reactivation in myeloma patients have not been reported extensively. We describe here two cases of HBV reactivation in HBsAg-negative myeloma patients receiving systemic chemotherapy: one from the medical records of 40 patients and another from 61 patients with prospective HBV-DNA monitoring. In the first case positive for anti-HBs, HBV reactivation was diagnosed when hepatitis developed during conventional chemotherapy such as MP and MCP regimen in a relapsed patient after autologous stem cell transplantation (APBSCT); in the second case positive for anti-HBc and anti-HBs, elevation of HBV-DNA was recognized by serial HBV-DNA monitoring performed prospectively following APBSCT. Interestingly, these two cases had the reduction of the titer of anti-HBs during the treatment, followed by HBV reactivation. These clinical data suggest that the HBV-DNA monitoring is necessary for not only HBsAg-positive but also HBsAg-negative myeloma patients with anti-HBc-positive and/or anti-HBs-positive following transplantation and after conventional chemotherapy in the salvage setting. Establishment of a standard strategy to prevent HBV reactivation is important for myeloma patients receiving systemic chemotherapy.

Keywords

Reactivation HBV Myeloma Transplantation 

Abbreviations

HBV

Hepatitis B virus

HBsAg

Hepatitis B surface antigen

Anti-HBc

Hepatitis B core antibody

Anti-HBs

Hepatitis B surface antibody

AST

Aspartate transaminase

ALT

Alanine aminotransferase

RTD-PCR

Real-time detection polymerase chain reaction

APBSCT

Autologous peripheral blood stem cell transplantation

VAD

Vincristine, doxorubicin, dexamethasone

MP

Melphalan, prednisolone

MCP

Ranimustine, cyclophosphamide, prednisolone

MMCP

Melphalan, ranimustine, cyclophosphamide, prednisolone

BD

Bortezomib, dexamethasone

TD

Thalidomide, dexamethasone

CHOP

Cyclophosphamide, doxorubicin, vincristine, prednisolone

R-CHOP

Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone

References

  1. 1.
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182–8.PubMedGoogle Scholar
  2. 2.
    Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.CrossRefPubMedGoogle Scholar
  4. 4.
    Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, et al. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology. 2009;136:652–62.e3.CrossRefPubMedGoogle Scholar
  7. 7.
    Endo T, Sawada K, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, et al. Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies. Rinsho Ketsueki. 2000;41:322–8.PubMedGoogle Scholar
  8. 8.
    Uhm JE, Kim K, Lim TK, Park BB, Park S, Hong YS, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:463–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997;8(Suppl 1):107–9.CrossRefPubMedGoogle Scholar
  10. 10.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet. 2007;370:1209–18.CrossRefPubMedGoogle Scholar
  12. 12.
    Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20.PubMedGoogle Scholar
  14. 14.
    Tanaka E, Umemura T. History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. Clin J Gastroenterol. 2008;1:83–6.CrossRefGoogle Scholar
  15. 15.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.CrossRefPubMedGoogle Scholar
  16. 16.
    Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013–7.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Tatsuya Yoshida
    • 1
  • Shigeru Kusumoto
    • 1
  • Atsushi Inagaki
    • 1
  • Fumiko Mori
    • 1
  • Asahi Ito
    • 1
  • Masaki Ri
    • 1
  • Takashi Ishida
    • 1
  • Hirokazu Komatsu
    • 1
  • Shinsuke Iida
    • 1
  • Fuminaka Sugauchi
    • 2
  • Yasuhito Tanaka
    • 2
  • Masashi Mizokami
    • 3
  • Ryuzo Ueda
    • 1
  1. 1.Department of Medical Oncology and ImmunologyNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Department of Virology and Liver UnitNagoya City University Graduate School of Medical SciencesNagoyaJapan
  3. 3.Research Center for Hepatitis and ImmunologyInternational Medical Center of Japan Konodai HospitalIchikawaJapan

Personalised recommendations